Thus, Smyca is a lncRNA that turns the dichotomous roles of TGF-β toward tumor promotion and represents a potential therapeutic target for cancers with aberrant activation of TGF-β and/or c-Myc pathways. Here, MIR23AHG is linked to neoplasm.